The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1132
June 10, 2002
View Complete Issue         Table of Contents 2019 
Tazarotene (Tazorac) for Acne
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tazarotene (Tazorac) for Acne
June 10, 2002 (Issue: 1132)
Tazarotene (taz ar' oh teen, Tazorac - Allergan), an acetylinic retinoid marketed for treatment of psoriasis (Medical Letter 1997; 39:105), is also available as a 0.1% gel and cream for treatment of acne.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tazarotene (Tazorac) for Acne
Article code: 1132b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.